BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SYS6010: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: CSPC Megalith Biopharmaceutical Co.,Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-12-12 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNSCLCnot yet recruiting680

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-07-30 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)EGFR-mutated Locally Advanced or Metastatic NSCLCrecruiting380

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.